Novartis Expands Biologics Production in France
Jacobs Engineering will provide engineering and construction services to expand the Novartis site in Huningue, France.
Jacobs Engineering Group was awarded a contract to expand the Novartis Pharma S.A.S. Biotechnology Center in Huningue, France, the company announced on Aug. 11, 2016. Under the terms of the agreement, Jacobs is providing engineering, procurement, and construction management services to increase the site’s production capacity by 70% and create a second line of purification that allows for multiple drugs to be manufactured simultaneously.
Already one of the world’s largest production facilities for monoclonal antibodies from mammalian cells, the expansion project adds cell culture bioreactors to the site. The $100 million expansion project is scheduled to be completed in four years. Jacobs’ services are being led from its operations in Milan, Italy.
Source: Jacobs Engineering
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
